Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Refractory Adult-Onset Still's Disease
NCT07151157Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in adult-onset Still's disease (AOSD), sponsored by Ruijin Hospital. Primary endpoint: Adult-Onset Still's Disease Activity Score at 12 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT07151157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151157.